Carrara Exploration (C: CAA) to amalgamate with PreveCeutical in RTO
If You’re Thinking About a Side Hustle…
Relevium is Ready to Roll — Q&A with CEO Aurelio Useche
How America’s Crumbling Infrastructure Could Be an Investor’s Best Friend
Pressure BioSciences, Inc. (PBIO) Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Business Update
Patrick Wheeler of ARCA biopharma explains its genetically-targeted therapies for cardiovascular diseases, and its lead product candidate.
You have to be logged in to leave a comment.
I'm sorry, but in order to complete what you're trying to do, you must be logged in.
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).